Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

References for PMC Articles for PubMed (Select 19186350)

1.

Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study.

Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, Young M, Justman JE.

AIDS. 2007 Aug 20;21(13):1739-45.

PMID:
17690572
2.

Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution.

Cox C, Chu H, Schneider MF, Muñoz A.

Stat Med. 2007 Oct 15;26(23):4352-74.

PMID:
17342754
3.

Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy.

Shlay JC, Bartsch G, Peng G, Wang J, Grunfeld C, Gibert CL, Visnegarwala F, Raghavan SS, Xiang Y, Farrough M, Perry HE, Kotler D, El-Sadr WM.

J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):506-17.

PMID:
17325603
4.

Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults.

Fleischman A, Johnsen S, Systrom DM, Hrovat M, Farrar CT, Frontera W, Fitch K, Thomas BJ, Torriani M, Côté HC, Grinspoon SK.

Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1666-73. Epub 2007 Feb 6.

5.

Relation of stavudine discontinuation to anthropometric changes among HIV-infected women.

Tien PC, Schneider MF, Cole SR, Justman JE, French AL, Young M, DeHovitz J, Nathwani N, Brown TT.

J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):43-8.

PMID:
17091021
6.

Fat distribution in women with HIV infection.

Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM).

J Acquir Immune Defic Syndr. 2006 Aug 15;42(5):562-71.

7.

The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection.

Lo JC, Kazemi MR, Hsue PY, Martin JN, Deeks SG, Schambelan M, Mulligan K.

Clin Infect Dis. 2005 Nov 1;41(9):1335-40. Epub 2005 Sep 29.

8.

Fat distribution in men with HIV infection.

Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM).

J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):121-31.

9.

Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction.

Shikuma CM, Day LJ, Gerschenson M.

Curr Drug Targets Infect Disord. 2005 Sep;5(3):255-62. Review.

PMID:
16181144
10.

The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench.

Bacon MC, von Wyl V, Alden C, Sharp G, Robison E, Hessol N, Gange S, Barranday Y, Holman S, Weber K, Young MA.

Clin Diagn Lab Immunol. 2005 Sep;12(9):1013-9. Review. No abstract available.

11.

Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.

Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, Chmiel JS, Visscher BR, Margolick JB, Dobs AS.

AIDS. 2005 Sep 2;19(13):1375-83.

PMID:
16103768
12.

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.

Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong N, Freund J, Cooper DA; Mitochondrial Toxicity Study Group.

AIDS. 2004 Apr 30;18(7):1029-36.

PMID:
15096806
13.

The metabolic effects of lopinavir/ritonavir in HIV-negative men.

Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M, Grunfeld C.

AIDS. 2004 Mar 5;18(4):641-9.

14.

Ethnic differences in insulin sensitivity and beta-cell function in premenopausal or early perimenopausal women without diabetes: the Study of Women's Health Across the Nation (SWAN).

Torréns JI, Skurnick J, Davidow AL, Korenman SG, Santoro N, Soto-Greene M, Lasser N, Weiss G; Study of Women's Health Across the Nation (SWAN).

Diabetes Care. 2004 Feb;27(2):354-61.

PMID:
14747213
15.

Combination antiretroviral therapy and the risk of myocardial infarction.

Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group.

N Engl J Med. 2003 Nov 20;349(21):1993-2003. Erratum in: N Engl J Med. 2004 Feb 26;350(9):955.

16.

Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.

Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L, Lai S, Young M, Cohen M, Muñoz A.

Am J Epidemiol. 2003 Oct 1;158(7):687-94.

17.

Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era.

Vittecoq D, Escaut L, Chironi G, Teicher E, Monsuez JJ, Andrejak M, Simon A.

AIDS. 2003 Apr;17 Suppl 1:S70-6. Review.

PMID:
12870533
18.

Coronary heart disease in HIV-infected individuals.

Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, Maa JF, Hodder S.

J Acquir Immune Defic Syndr. 2003 Aug 1;33(4):506-12.

PMID:
12869840
19.

Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

John M, McKinnon EJ, James IR, Nolan DA, Herrmann SE, Moore CB, White AJ, Mallal SA.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):29-33.

PMID:
12792352
20.

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

Klein D, Hurley LB, Quesenberry CP Jr, Sidney S.

J Acquir Immune Defic Syndr. 2002 Aug 15;30(5):471-7.

PMID:
12154337
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk